Drug Trial Radar · NCT07807449
Safety and Preliminary Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Adults Aged 18 Years and Older
Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
128
Planned (sponsor's estimate)
Start
Sep 15, 2026
Primary completion
Jan 22, 2027
Study completion Jan 22, 2029
Sponsor
- Lead sponsor
- Yikang Biotech (Suzhou) Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Jiangsu Province Centers for Disease Control and Prevention
- First posted
- Sep 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This phase 1 study in China will evaluate the Safety and Preliminary Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Adults Aged 18 Years and Older
Conditions
- Respiratory Syncytial Virus (RSV)
Interventions
Recombinant RSV Vaccine (CHO Cell)Biological
0.4 mL per dose
Recombinant RSV Vaccine (CHO Cell)Biological
0.8 mL per dose
Adjuvant SuspensionBiological
0.9 mL per dose
Recombinant RSV Vaccine (CHO Cell) with Adjuvant SuspensionBiological
0.9 mL per dose
Saline solutionBiological
0.9 mL per dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of immediate adverse eventsTime frame: Within 30 minutes after vaccination
- Incidence of solicited AEsTime frame: Within 0-14 days after vaccination
- Incidence of unsolicited AEsTime frame: Within 30 days after vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Yixing People's Hospital
Yixing, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.